Inhibition of Hepatitis C Virus Infection by DNA Aptamer against Envelope Protein
Open Access
- 1 October 2013
- journal article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 57 (10) , 4937-4944
Abstract
Hepatitis C virus (HCV) envelope protein (E1E2) is essential for virus binding to host cells. Aptamers have been demonstrated to have strong promising applications in drug development. In the current study, a cDNA fragment encoding the entire E1E2 gene of HCV was cloned. E1E2 protein was expressed and purified. Aptamers for E1E2 were selected by the method of selective evolution of ligands by exponential enrichment (SELEX), and the antiviral actions of the aptamers were examined. The mechanism of their antiviral activity was investigated. The data show that selected aptamers for E1E2 specifically recognize the recombinant E1E2 protein and E1E2 protein from HCV-infected cells. CD81 protein blocks the binding of aptamer E1E2-6 to E1E2 protein. Aptamers against E1E2 inhibit HCV infection in an infectious cell culture system although they have no effect on HCV replication in a replicon cell line. Beta interferon (IFN-β) and IFN-stimulated genes (ISGs) are not induced in virus-infected hepatocytes with aptamer treatment, suggesting that E1E2-specific aptamers do not induce innate immunity. E2 protein is essential for the inhibition of HCV infection by aptamer E1E2-6, and the aptamer binding sites are located in E2. Q412R within E1E2 is the major resistance substitution identified. The data indicate that an aptamer against E1E2 exerts its antiviral effects through inhibition of virus binding to host cells. Aptamers against E1E2 can be used with envelope protein to understand the mechanisms of HCV entry and fusion. The aptamers may hold promise for development as therapeutic drugs for hepatitis C patients.Keywords
This publication has 36 references indexed in Scilit:
- Innate Host Response in Primary Human Hepatocytes with Hepatitis C Virus InfectionPLOS ONE, 2011
- Hepatitis C virus resistance to protease inhibitorsJournal of Hepatology, 2011
- Inhibition of HIV transmission in human cervicovaginal explants and humanized mice using CD4 aptamer-siRNA chimerasJournal of Clinical Investigation, 2011
- Protection of HIV Neutralizing Aptamers against Rectal and Vaginal NucleasesJournal of Biological Chemistry, 2011
- A New Paradigm for Aptamer Therapeutic AS1411 Action: Uptake by Macropinocytosis and Its Stimulation by a Nucleolin-Dependent MechanismCancer Research, 2010
- Human occludin is a hepatitis C virus entry factor required for infection of mouse cellsNature, 2009
- Production of infectious genotype 1a hepatitis C virus (Hutchinson strain) in cultured human hepatoma cellsProceedings of the National Academy of Sciences, 2006
- Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular diseaseNature Reviews Drug Discovery, 2006
- The human scavenger receptor class B type I is a novel candidate receptor for the hepatitis C virusThe EMBO Journal, 2002
- Systematic Evolution of Ligands by Exponential Enrichment: RNA Ligands to Bacteriophage T4 DNA PolymeraseScience, 1990